Vertex Pharmaceuticals Inc VRTX:NASDAQ

Last Price$184.15Cboe Closing Price as of 4:00PM ET 8/22/19
Cboe Real-Time Quotes
Today's Change-2.25(1.21%)
Bid (Size)$172.32 (100)
Ask (Size)$193.94 (100)
Day Low / High$181.77 - 187.62
Volume593.2 K

View Biotechnology IndustryPeer Comparison as of 08/22/2019


Vertex Pharmaceuticals Inc ( NASDAQ )

Price: $184.15
Change: -2.25 (1.21%)
Volume: 593.2 K
4:00PM ET 8/22/2019

Biogen Inc ( NASDAQ )

Price: $232.67
Change: -0.51 (0.22%)
Volume: 444.8 K
3:46PM ET 8/22/2019

Illumina Inc ( NASDAQ )

Price: $289.49
Change: -1.01 (0.35%)
Volume: 335.9 K
3:46PM ET 8/22/2019

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Regeneron Pharmaceuticals Inc ( NASDAQ )

Price: $295.82
Change: -1.96 (0.66%)
Volume: 330.1 K
3:46PM ET 8/22/2019

Read more news Recent News

FDA Accepts Vertex Pharmaceuticals' New Drug Application for Cystic Fibrosis Triple Combination Regimen
8:40AM ET 8/20/2019 MT Newswires

Vertex Pharmaceuticals (VRTX) said pre-market Tuesday that the US Food and Drug Administration has accepted its New Drug Application (NDA) for the VX-445...

Moderna Surges 7% on Pipeline Update, Further Collaboration With Vertex; Q2 Revenue Lower Than Expected
3:33PM ET 8/07/2019 MT Newswires

Moderna (MRNA) shares rose 7% in afternoon trade Wednesday after sharing a pipeline update and announced the extension of its agreement with Vertex (VRTX)....

Analysts' Scale Up Vertex Pharmaceuticals' 2019, 2020 Earnings Estimates
12:56PM ET 8/03/2019 MT Newswires

Vertex Pharmaceuticals Inc's (NASDAQ:VRTX, Recent Price: 178.39) full year forecasted earnings estimates for 2019 and 2020 have been increased. The...

Analysts' Increase Vertex Pharmaceuticals' Q3, 2019, 2020 Earnings Estimates
11:36AM ET 8/02/2019 MT Newswires

Q3, 2019, and 2020`s consensus estimates for Vertex Pharmaceuticals Inc (NASDAQ:VRTX, Recent Price: 179.29) have been revised upward. The Q3 earnings...

View all Commentary and Analysis

The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron
10:55AM ET 8/22/2019 Zacks

The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron

The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron
10:55AM ET 8/22/2019 Zacks

The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron

Goodbye To Gilead As ViiV, Merck Besiege Its HIV Citadel
1:34PM ET 8/18/2019 Seeking Alpha

Q2 Biotech Updates
8:49AM ET 8/12/2019 Seeking Alpha

Company Profile

Business DescriptionVertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA. View company web site for more details
Address50 Northern Avenue
Boston, Massachusetts 02210
Number of Employees2,500
Recent SEC Filing08/20/20194
Chairman, President & Chief Executive OfficerJeffrey M. Leiden
Chief Financial Officer & Executive Vice PresidentCharles F. Wagner
Chief Scientific Officer & EVP-Global ResearchDavid Matthew Altshuler
Chief Medical Officer & Executive Vice PresidentReshma Kewalramani

Company Highlights

Price Open$186.76
Previous Close$186.40
52 Week Range$151.80 - 195.81
Market Capitalization$47.3 B
Shares Outstanding257.0 M
SectorHealth Technology
Next Earnings Announcement10/23/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings21.68
Earnings per Share$8.44
Beta vs. S&P 500N/A
Revenue$3.0 B
Net Profit Margin64.55%
Return on Equity51.71%

Analyst Ratings as of 08/01/2019

Consensus RecommendationConsensus Icon
Powered by Factset